Related Experiment Video
Updated: Sep 5, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
Dissecting the Roles of PDCD4 in Breast Cancer
Qian Cai1,2, Hsin-Sheng Yang3, Yi-Chen Li4
1Department of Geriatric Medicine, Qilu Hospital of Shandong University, Jinan, China.
Abstract:
The human programmed cell death 4 (PDCD4) gene was mapped at chromosome 10q24 and encodes the PDCD4 protein comprised of 469 amino acids. PDCD4 inhibits protein translation PDCD4 inhibits protein translation to suppress tumor progression, and its expression is frequently decreased in breast cancer. PDCD4 blocks translation initiation complex by binding eIF4A via MA-3 domains or by directly binding 5' mRNA internal ribosome entry sites with an RNA binding domain to suppress breast cancer progression and proliferation. Numerous regulators and biological processes including non-coding RNAs, proteasomes, estrogen, natural compounds and inflammation control PDCD4 expression in breast cancer. Loss of PDCD4 expression is also responsible for drug resistance in breast cancer. HER2 activation downregulates PDCD4 expression by activating MAPK, AKT, and miR-21 in aromatase inhibitor-resistant breast cancer cells. Moreover, modulating the microRNA/PDCD4 axis maybe an effective strategy for overcoming chemoresistance in breast cancer. Down-regulation of PDCD4 is significantly associated with short overall survival of patients, which suggests that PDCD4 may be an independent prognostic marker for breast cancer.
Insights
Programmed cell death 4 (PDCD4) suppresses tumor growth and its reduced expression is linked to breast cancer progression and drug resistance. Restoring PDCD4 levels may improve patient survival and treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Programmed cell death 4 (PDCD4) is a tumor suppressor protein that inhibits translation.
- PDCD4 expression is frequently downregulated in breast cancer, correlating with tumor progression and proliferation.
- Loss of PDCD4 is implicated in drug resistance and poor prognosis in breast cancer patients.
Purpose of the Study:
- To investigate the role of PDCD4 in breast cancer progression, drug resistance, and as a prognostic marker.
- To explore regulatory mechanisms controlling PDCD4 expression in breast cancer.
- To evaluate the therapeutic potential of targeting the microRNA/PDCD4 axis.
Main Methods:
- Gene mapping of PDCD4 to chromosome 10q24.
- Analysis of PDCD4 protein structure and function in translation inhibition.
- Investigation of PDCD4 regulation by non-coding RNAs, signaling pathways (MAPK, AKT), and HER2 activation.
- Correlation analysis of PDCD4 expression with patient survival and drug resistance.
Main Results:
- PDCD4 inhibits protein translation by interacting with translation initiation factors and mRNA.
- PDCD4 expression is decreased in breast cancer due to various regulators, including miR-21.
- HER2 activation downregulates PDCD4, contributing to aromatase inhibitor resistance.
- Reduced PDCD4 expression is significantly associated with shorter overall survival in breast cancer patients.
Conclusions:
- PDCD4 is a critical tumor suppressor in breast cancer, inhibiting proliferation and progression.
- Modulating the microRNA/PDCD4 axis presents a potential strategy to overcome chemoresistance.
- PDCD4 serves as an independent prognostic marker for breast cancer, with its downregulation indicating a poor outlook.
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
Negative Regulator Molecules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
DNA Damage can Stall the Cell Cycle
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...

